Improvement and validation of an HPLC method for examining the effects of the MDR1 gene polymorphism on sparfloxacin pharmacokinetics

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 834, Issue 1-2, 2006, Pages 84-92

  Cho, Hea Young ^a   Park, Sun Ae ^a   Lee, Yong Bok ^a,b  

^a Chonnam National University   (South Korea)

^b Chonnam National University Medical School   (South Korea)

Author keywords

MDR1; Pharmacokinetics; Sparfloxacin

Indexed keywords

BIOLOGICAL ORGANS; CHROMATOGRAPHIC ANALYSIS; GENES; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; PARAMETER ESTIMATION; PHARMACOKINETICS; PRECIPITATION (CHEMICAL); PROTEINS;

HUMAN SERUM; LINEAR RESPONSES; MDR1; SPARFLOXACIN;

GENETIC ENGINEERING;

ACETONITRILE; CIPROFLOXACIN; MULTIDRUG RESISTANCE PROTEIN 1; PERCHLORIC ACID; SPARFLOXACIN; TRIETHYLAMINE;

ACCURACY; ADULT; ARTICLE; ASSAY; CHROMATOGRAPHY; CONCENTRATION RESPONSE; CORRELATION COEFFICIENT; DRUG BLOOD LEVEL; EXON; FEMALE; GENETIC POLYMORPHISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PH; PRECIPITATION; PRIORITY JOURNAL; QUALITY CONTROL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SENSITIVITY ANALYSIS; STATISTICAL SIGNIFICANCE; ULTRAVIOLET RADIATION; VALIDATION PROCESS;

ANTI-BACTERIAL AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FLUOROQUINOLONES; GENES, MDR; POLYMORPHISM, GENETIC; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SPECTROPHOTOMETRY, ULTRAVIOLET;

EID: 33645971659     PISSN: 15700232     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchromb.2006.02.033     Document Type: Article

References (19)

1. Montay G. J. Antimicrob. Chemother. 37 Suppl. A (1996) 27
2. Gidoh M., and Tsutsumi S. Lepr. Rev. 63 (1992) 108
3. Goa K.L., Bryson H.M., and Markham A. Drugs 53 (1997) 700
4. Schentag J.J. Clin. Ther. 22 (2000) 372
5. Matsunaga Y., Miyazaki H., Oh-e Y., Nambu K., Furukawa H., Yoshida K., and Hashimoto M. Arzneim. -Forsch./Drug Res. 41 (1991) 747
6. Shimada J., Nogita T., and Ishibashi Y. Clin. Pharmacokinet. 25 (1993) 358
7. Cormet-Boyaka E., Huneau J.-F., Mordrelle A., Boyaka P.N., Carbon C., Rubinstein E., and Tome D. Antimicrob. Agents Chemother. 42 (1998) 2607
8. de Lange E.C., Marchand S., van den Berg D., van der Sandt I.C., de Boer A.G., Delon A., Bouquet S., and Couet W. Eur. J. Pharm. Sci. 12 (2000) 85
9. Siegmund W., Ludwig K., Giessmann T., Dazert P., Schroeder E., Sperker B., Warzok R., Kroemer H.K., and Cascorbi I. Clin. Pharmacol. Ther. 72 (2002) 572
10. Kroetz D.L., Pauli-Magnus C., Hodges L.M., Huang C.C., Kawamoto M., Johns S.J., Stryke D., Ferrin T.E., DeYoung J., Taylor T., Carlson E.J., Herskowitz I., Giacomini K.M., and Clark A.G. Pharmacogenetics 13 (2003) 481
11. Chowbay B., Cumaraswamy S., Cheung Y.B., Zhou Q., and Lee E.J. Pharmacogenetics 13 (2003) 89
12. Kurobe N., Ohue T., Tamaguchi T., and Nakamura S. Chemotherapy 39 Suppl. 4 (1991) 116
13. Mody V.D., Pandya K.K., Satia M.C., Modi I.A., Modi R.I., and Gandhi T.P. J. Pharm. Biomed. Anal. 19 (1998) 1289
14. Kamberi M., Kamberi P., Hajime N., Uemura N., Nakamura K., and Makano S. Ther. Drug Monit. 21 (1999) 411
15. Borner K., Borner E., and Lode H. J. Chromatogr. B 579 (1992) 285
16. Vander Heyden Y., Nijhuis A., Smeyers-Verbeke J., Vandeginste B.G., and Massart D.L. J. Pharm. Biomed. Anal. 24 (2001) 723
17. Hund E., Vander Heyden Y., Haustein M., Massart D.L., and Smeyers-Verbeke J. J. Chromatogr. A 874 (2000) 167
18. WinNonlin™, Users Guide, Ver. 3.0, Pharsight Corp., Mountain View, CA, USA, 1998-1999.
19. http://anthro.unige.ch/arlequin.